drugset / Trial / NCT01525823

Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With Metformin

NCT01525823

Phase 1 Completed 26 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-label

Summary

The purpose of this study is to assess the effects of Metformin administered over two weeks on the peak plasma glucose concentrations following administration of BMS-754807.

Timeline

Start
2012-02
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-754807 Small molecule 100 mg Oral
Subject Metformin Small molecule 2000 mg Oral

Indications

No indication recorded.